Elanco Animal Health Reports Third Quarter 2026 Financial Results

Elanco Animal Health reported third-quarter 2026 revenue of $1.265 billion, up 11% year over year, including 9% organic constant-currency growth. Net income was $18 million, while adjusted net income was $136 million and adjusted EPS was $0.27, above analyst expectations; adjusted EBITDA was $243 million, with a 19.5% margin. The company issued fourth-quarter guidance, updated its 2026 outlook, and provided an initial 2027 financial outlook. CEO Jeff Simmons said the results reflected consistent growth and accelerating cash flow.